|
Neuromed Names Sean Cunliffe Chief Commercial Officer CONSHOHOCKEN, PA and VANCOUVER, BC, April 29 /CNW/ - Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, today announced the promotion of Sean Cunliffe to Chief Commercial Officer. Mr. Cunliffe will lead all pre- and post-approval commercial activities of Neuromed's product candidates, including NMED-1077 (OROS(R) Hydromorphone) in Phase 3 clinical development for the treatment of moderate-to-severe chronic pain. Read the rest of the release. CANTEST welcomes new Vice President of Sales and Marketing March 12, 2008 Burnaby, British Columbia - CANTEST is pleased to announce the appointment of Brian Lowe as Vice President, Sales and Marketing. Read more. Xenon Announces Appointment of VP, Discovery Research Vancouver, Canada (February 4, 2008) - Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Charles J. Cohen as Vice President, Discovery Research. "We are delighted to welcome Charlie to the Xenon team" commented Simon Pimstone, Xenon's President and CEO. Read more. Wellichem Dr. Hugh Wynne-Edwards Resigns as a Director and Chairman of the Board BURNABY, BC, April 8, 2008 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced that Dr. Hugh Wynne-Edwards has resigned as a director and Chairman of the Board from the Company due to health reasons. The Company has valued Dr. Wynne-Edwards’ contribution as a director and Chairman of the Board for many years. Read more. Welichem Announces Change of Board Members BURNABY, BC, Jan. 25 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Mr. Weihe Wang and Mr. Zhaofang Zhang resigned as directors of the Company and that Mr. Wenfeng Liu and Ms. Mingrong Lu joined the Company as directors, effective January 24, 2008. The Company would like to thank Mr. Wang and Mr. Zhang for their valued contribution to the Company. Read more. Inflazyme Pharmaceuticals Announces Departure of Senior Management December 28, 2007 VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd., (IZP.H) announced today that Dr. Kevin Mullane, President and C.E.O., Dr. David Burgoyne, V.P. Business Development, and Dr. John Langlands, Senior Director, Clinical Research will be leaving the Company on January 1,2008, to pursue new opportunities. Their departure will further reduce the burn of the Company during its final stages of reconciling the best steps for enhanced shareholder value after the close of the Biolipox transaction on November 19, 2007. Read more. |
 Suite 900 - 1188 West Georgia St.
Vancouver, BC V6E 4A2 |